Pharmacodynamic variability beyond that explained by MICs
- PMID: 23357773
- PMCID: PMC3623339
- DOI: 10.1128/AAC.01224-12
Pharmacodynamic variability beyond that explained by MICs
Abstract
Monte Carlo simulations (MCS) present a powerful tool to evaluate candidate regimens by determining the probability of target attainment. Although these assessments have traditionally incorporated variability in pharmacokinetic (PK) parameters and MICs, consideration of interstrain pharmacodynamic (PD) variability has been neglected. A population PK/PD model was developed for doripenem using murine thigh infection data based on 20 bacterial strains. PK data were fit to a linear two-compartment model with first-order input and elimination processes and an absorption lag time from a separate site (r(2) > 0.96). PK parameters were utilized to simulate free-drug profiles for various regimens in PD studies, from which the percentage of the dosing interval for which free-drug concentrations exceed the MIC of the targeted strain (%fT>MIC) was calculated. Doripenem PD was excellently described with Hill-type models (r(2) > 0.98); significant differences between mean PD estimates determined using a two-stage approach versus population analyses were not observed (P > 0.05); however, the variance in 50% effective concentration (EC50) and maximum effect (Emax) among strains was much greater using the two-stage approach. Even using the population approach, interstrain variability in EC50 (coefficient of variation expressed as a percentage [CV%] = 29.2%) and H (CV% = 46.1%) parameters was substantive, while the variability in Emax (CV% = 19.7%) was modest. This resulted in extensive variability in the range of %fT>MIC targets associated with stasis to those associated with a 2-log10 reduction in bacterial burden (CV% ∼ 50%). It appears that MCS, based on the assumption that PD variability is due to MIC alone, underestimates variability and may consequently underestimate treatment failures.
Figures



Similar articles
-
Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.Ann Pharmacother. 2017 Mar;51(3):209-218. doi: 10.1177/1060028016676831. Epub 2016 Nov 13. Ann Pharmacother. 2017. PMID: 28168884
-
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.Antimicrob Agents Chemother. 2010 Jun;54(6):2360-4. doi: 10.1128/AAC.01843-09. Epub 2010 Apr 12. Antimicrob Agents Chemother. 2010. PMID: 20385857 Free PMC article.
-
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.Surg Infect (Larchmt). 2016 Dec;17(6):675-682. doi: 10.1089/sur.2015.113. Epub 2016 Nov 14. Surg Infect (Larchmt). 2016. PMID: 27841954
-
Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?Enferm Infecc Microbiol Clin. 2014 Dec;32 Suppl 4:33-40. doi: 10.1016/S0213-005X(14)70172-7. Enferm Infecc Microbiol Clin. 2014. PMID: 25542050 Review.
-
Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.Clin Ther. 2016 Sep;38(9):2016-31. doi: 10.1016/j.clinthera.2016.08.001. Epub 2016 Aug 30. Clin Ther. 2016. PMID: 27586127 Review.
Cited by
-
Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0139423. doi: 10.1128/aac.01394-23. Epub 2024 Jan 30. Antimicrob Agents Chemother. 2024. PMID: 38289076 Free PMC article.
-
Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice.Antimicrob Agents Chemother. 2023 May 17;67(5):e0019723. doi: 10.1128/aac.00197-23. Epub 2023 Apr 6. Antimicrob Agents Chemother. 2023. PMID: 37022153 Free PMC article.
-
Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man.Front Pharmacol. 2022 Mar 18;13:833189. doi: 10.3389/fphar.2022.833189. eCollection 2022. Front Pharmacol. 2022. PMID: 35370708 Free PMC article. Review.
-
Tissue penetration of antifungal agents.Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. Clin Microbiol Rev. 2014. PMID: 24396137 Free PMC article. Review.
-
In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.J Antimicrob Chemother. 2022 Dec 23;78(1):93-100. doi: 10.1093/jac/dkac359. J Antimicrob Chemother. 2022. PMID: 36272135 Free PMC article.
References
-
- Ortho-McNeil Pharmaceutical 2007. Doribax package insert. Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ
-
- Livermore DM. 2009. Doripenem: antimicrobial profile and clinical potential. Diagn. Microbiol. Infect. Dis. 63:455–458 - PubMed
-
- AstraZeneca 2007. Merrem package insert. AstraZeneca, Wilmington, DE
-
- Merck & Co 2006. Primaxin IV package insert. Merck & Co., Inc., Whitehouse Station, NJ
-
- Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. 2009. Overview of seizure-inducing potential of doripenem. Drug Saf. 32:709–716 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical